

## Supplemental materials

### Effect of Nipocalimab on IgG Responses to Vaccinations and Viral Infections in Patients with IgG Autoantibody–Mediated Diseases: Post Hoc Analyses of 3 Randomized, Placebo-Controlled Trials

**Table S1. Concomitant Corticosteroid and Immunosuppressant Use in Individual Participants Who Received TT or SARS-CoV-2 Vaccines**

Study	Treatment group	Participant	Vaccine received	Systemic corticosteroids received	Immunosuppressants received
Vivacity-MG3	Nipocalimab	Nipocalimab 1	TT	Prednisone (10 mg QD)	None
		Nipocalimab 2	COVID-19	Prednisone (10 mg QD) <sup>a</sup> , methylprednisolone sodium succinate (40 mg QD) <sup>a</sup>	Azathioprine (50 mg TID) <sup>a</sup>
		Nipocalimab 3	COVID-19	Prednisone (20 mg QD)	None
		Nipocalimab 4	COVID-19	Prednisolone (5 mg QD)	Tacrolimus (2 mg QD)
		Nipocalimab 5	COVID-19	None	Azathioprine (50 mg QD)
		Nipocalimab 6	COVID-19	Prednisone (5 mg QD)	Mycophenolate mofetil (1500 mg BID)
		Nipocalimab 7	COVID-19	Methylprednisolone (16 mg QD)	Mycophenolate mofetil (1250 mg BID)
		Nipocalimab 8	COVID-19	None	None
		Nipocalimab 9	COVID-19	Prednisolone (5 mg QOD)	None
		Nipocalimab 10	COVID-19	Prednisolone (10 mg QD), methylprednisolone sodium succinate (1000 mg QD) <sup>a</sup>	Tacrolimus (3 mg QD)


		Nipocalimab 11	COVID-19	Prednisolone (10 mg QD)	Cyclosporine (150 mg BID)
		Nipocalimab 12	COVID-19	Prednisolone (3 mg QD)	Tacrolimus (2 capsule QD)
		Nipocalimab 13	COVID-19	Prednisone (75 mg QD)	Azathioprine (200 mg QD)
	Placebo	Placebo 29	DPT	Prednisone (5 mg QOD)	Cyclosporine (100 mg BID)
		Placebo 30	TT	Methylprednisolone (16 mg QOD)	Mycophenolate mofetil (1000 mg BID)
		Placebo 1	COVID-19	Prednisone (20 mg QD)	None
		Placebo 2	COVID-19	Methylprednisolone (8 mg BID)	None
		Placebo 3	COVID-19	Methylprednisolone (4 mg QD)	Mycophenolate mofetil (500 mg BID), cyclosporine (50 mg TID)
		Placebo 4	COVID-19	None	None
		Placebo 5	COVID-19	Prednisone (5 mg QD)	Azathioprine (50 mg BID)
		Placebo 6	COVID-19	None	Mycophenolate mofetil (1000 mg BID)
		Placebo 7	COVID-19	Prednisolone (10 mg QD)	Cyclosporine (150 mg BID)
		Placebo 8	COVID-19	Prednisolone (5 mg QD)	None
		Placebo 9	COVID-19	Prednisolone (15 mg QD)	None
		Placebo 10	COVID-19	Prednisolone (11 mg QD)	Cyclosporine (100 mg BID)
		Placebo 11	COVID-19	Prednisolone (5 mg QD)	Azathioprine (100 mg QD)
		Placebo 12	COVID-19	Prednisone (5 mg QD)	Mycophenolate mofetil (1500 mg BID)
<b>IRIS-RA</b>	Nipocalimab	Nipocalimab 14	COVID-19	None	Methotrexate (25 mg QW, SC)
		Nipocalimab 15	COVID-19	Methylprednisolone (4 mg QD)	Methotrexate (15 mg QW)
		Nipocalimab 16	COVID-19	Prednisolone (10 mg QD)	None
	Placebo	Placebo 13	COVID-19	Prednisolone (5 mg QD)	None
		Placebo 14	COVID-19	None	Methotrexate sodium (20 mg QW)
		Placebo 15	COVID-19	Methylprednisolone (4 mg QD)	Methotrexate (20 mg QW)
<b>DAHLIAS</b>	Nipocalimab	Nipocalimab 17	COVID-19	None	None
		Nipocalimab 18	COVID-19	None	None

	Placebo	Placebo 16	COVID-19	None	None
		Placebo 17	COVID-19	None	None

BID, twice daily; COVID-19, coronavirus disease 2019; DPT, diphtheria, pertussis, and tetanus vaccine; QD, once daily; QOD, every other day; QW, weekly; SC, subcutaneous; TID, three times daily; TT, tetanus toxoid.

<sup>a</sup>Medications were taken during trial period but not at time of vaccination.


**Figure S1. Anti-TT (A) specific IgG and (B) total IgG responses to the TT vaccination in individual participants treated with placebo in the Vivacity-MG3 study.**



IgG, immunoglobulin G; TT, tetanus toxoid.

<sup>a</sup>Protective threshold ( $\geq 0.16$  IU/mL) generally suggests a sufficient level of immunity to tetanus.<sup>14</sup>

**Figure S2. Total IgG response to SARS-CoV-2 vaccinations in individual participants treated with nipocalimab in (A) Vivacity-MG3, (B) IRIS-RA, and (C) DAHLIAS.**




COVID-19, coronavirus disease 2019; IgG, immunoglobulin G; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup>Participant received the last dose at Week 8.

<sup>b</sup>Participant missed the dose at Week 18 due to infection.

<sup>c</sup>Participant had both SAR-CoV-2 vaccination and infection during the treatment period and missed the dose at Week 10 due to infection.

**Figure S3. Total IgG response to SARS-CoV-2 infections in individual participants treated with nipocalimab in (A) Vivacity-MG3, (B) IRIS-RA, and (C) DAHLIAS.**



COVID-19, coronavirus disease 2019; IgG, immunoglobulin G; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup>Participant received the last dose at Week 4.

<sup>b</sup>Participant missed the dose at Week 6 due to infection.

<sup>c</sup>Participant missed the dose at Week 4 due to infection.

<sup>d</sup>Participant missed the dose at Week 18 due to infection.

<sup>e</sup>Participant had both SAR-CoV-2 vaccination and infection during the treatment period and missed the dose at Week 10 due to infection.

<sup>f</sup>Participant missed the dose at Week 2 due to infection.

<sup>g</sup>Participant delayed the dose from Week 10 to Week 12 due to infection.

<sup>h</sup>Participant missed the dose at Week 8.

<sup>i</sup>Participant missed the doses at Weeks 10 and 12.